Ovid Therapeutics

On this week's Tuesday Tips, Rachel features a very special guest! Tune in to learn about how she cares for her niece.   Keep up with the series and more of Rachel's work here: https://lnkd.in/eVuYtuvF #CCMAwareness #CCMWarriors #TuesdayTipswithRachel

Ovid would like to share warm wishes to those who celebrate Rosh Hashanah. Have a wonderful New Year, 5785.

Ovid’s President & COO Meg Alexander recently took the stage at the Fierce Biotech Summit, sharing insights on how companies can successfully pivot their pipeline in the wake of a setback. Drawing from her experiences at Ovid and working with other biopharma companies, Meg shared first-hand learnings that leaders can use to turn challenges into opportunities to rebuild and maximize their pipelines. See more details on Meg’s session here: https://lnkd.in/gZiJ8nHE

Last week, Ovid’s Chief Executive Officer, Dr. Jeremy M. Levin, and President & Chief Operating Officer, Meg Alexander, participated in a Q&A session at Cantor Fitzgerald’s 2024 Global Healthcare Conference. Jeremy and Meg gave an inside look into Ovid’s pipeline, highlighting programs including our library of novel KCC2 direct activators. Deficits in KCC2 activity have been associated with neuronal hyperexcitability, resulting in many neurological conditions. To learn more about Ovid’s pipeline, watch the full session: https://lnkd.in/e5mgKwky  #CantorHCC #epilepsy #CNS 

Whether facing a pipeline setback, managing asset transactions, or replacing sunsetting product revenues, most companies will eventually need to adapt their pipeline strategies. Today, Ovid’s President and COO, Meg Alexander, is presenting at the 2024 Fierce Biotech Summit to share key learnings from Ovid and other companies that have successfully navigated the challenges of pivoting and rebuilding a company’s pipeline. Say hi if you are at the event: https://lnkd.in/gZiJ8nHE

We’re pleased to present the results of a head-to-head animal study between OV329 and vigabatrin (VGB), the only FDA-approved GABA-aminotransferase (GABA-AT) inhibitor. Today’s findings suggest a compelling and potentially differentiated profile for OV329. The findings presented at the Epilepsy Pipeline Conference, showed that OV329 cleared and remained undetectable in the retinas, eyes, and brains of mice, suggesting a lack of accumulation. In contrast, this study shows, as has been seen in previous studies, VGB accumulates in these tissues. Full results from the head-to-head animal study will be presented at the 2024 American Epilepsy Society conference in December. Read the press release here: https://lnkd.in/eeaygviR

Join Rachel P. this week as she shares a few adaptive kitchen tools that help her with meal prep! Keep up with the series and more of Rachel's work here: https://lnkd.in/eVuYtuvF #CCMAwareness #CCMWarriors #TuesdayTipswithRachel

We’re delighted to share Meg Alexander is taking on an expanded role as President & Chief Operating Officer of Ovid, strengthening our leadership for future growth. Meg will oversee operations, research and development, corporate strategy, corporate affairs, human resources, and commercial strategy. She’ll work closely with our leadership team to advance our pipeline of potential disease-halting neurotherapeutics and define and execute Ovid’s go-forward strategy. With her extensive experience and proven track record in creating value for organizations, Meg will be instrumental in realizing the full potential of our libraries of novel ROCK2 inhibitors, KCC2 direct activators, and a GABA-aminotransferase inhibitor. Read the full press release here: https://lnkd.in/enqz-Qgd

Our CEO and Chairman, Dr. Jeremy M. Levin, will be presenting at H.C. Wainwright & Co., LLC's 26th Annual Global Investor Conference to highlight Ovid's commitment to advancing innovative neurological therapies. This year's gathering will showcase the latest innovations, current trends, and emerging technologies globally. #HCWainwrightGlobal

Happy Tuesday! This week, Rachel P. shares her tips on turning your living area into an adaptive space! Keep up with the series and more of Rachel's work here: https://lnkd.in/eVuYtuvF #CCMAwareness #CCMWarriors #TuesdayTipswithRachel